Dyadic International Inc (DYAI) - News Archive

Dyadic International Secures $3 Million Grant for Affordable Monoclonal Antibodies Amidst Financial StrugglesIntroductionDyadic International, Inc. (NASDAQ: DYAI), a burgeoning biotechnology company, recently announced...

Dyadic International Updates on Business Progress Amid Growing Focus on Alternative Proteins and Global Health Solutions JUPITER, Fla. September 23, 2024 Dyadic International, Inc. (NASDAQ: DYAI), a biotechnology compan...

Dyadic International, Inc., a prominent global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction, has recently partnered with Proliant Health and Biologicals (P...

Dyadic International, a leading biotechnology company specializing in large-scale protein manufacturing, recently made significant changes to its board and management leadership roles. The announcement included the step...

Dyadic International, a renowned global biotechnology company, has recently achieved a significant milestone with the publication of their latest study in Nature Communications. The study s groundbreaking findings showc...

Dyadic Announces $6.0 Million Private Placement to Drive Revenue Growth and Commercialization EffortsJUNIPER, Fla., March 11, 2024 - Dyadic International, Inc. (Dyadic or the Company), a pioneer in biotechnology, has ma...

Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, has recently made significant strides in its mission to provide accessible and affordable biopharmaceutical products for human and animal health...

DYADIC AND ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH COLLABORATE TO TACKLE BIO-THREATS AND EMERGING DISEASE SOLUTIONSJupiter, Fla. and Nes-Ziona, Israel, Feb. 23, 2024 - Dyadic International, Inc. (NASDAQ: DYAI), a renow...

Dyadic International, Inc. (Dyadic), a renowned biotechnology company specializing in advanced microbial platforms, and the Israel Institute for Biological Research (IIBR) have recently announced the advancement of thei...

Enhancing Quality Assurance in Biomanufacturing: Dyadic and Cygnus Technologies Partner to Provide C1 HCP ELISA AssayDyadic International Inc. (Dyadic) and Cygnus Technologies, part of Maravai LifeSciences, have recentl...

In a groundbreaking scientific development, Dyadic International Inc. has announced the successful completion of Phase 1 clinical trials for its first-of-its-kind filamentous fungal-based vaccine candidate. This excitin...